Late radiation effects to the rectum and anus after treatment for prostate cancer; validity of the LENT/SOMA score

References

• Milano MT, Constine LS, Okunieff P. Normal tissue tolerance dose metrics for radiation therapy of major organs. Semin Radiat Oncol 2007;17:131–40.
   PubMed Web of Science ®Google Scholar
• Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcomes. Int J Radiat Oncol Biol Phys 2005;63:1463–8.
   PubMed Web of Science ®Google Scholar
• Bolla M, Van Poppel H, Collette L, Van Cangh P, Vekemans K, Da Pozzo L, et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 2005;366:572–8.
   PubMed Web of Science ®Google Scholar
• Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial. Lancet 2009;373:301–8.
   PubMed Web of Science ®Google Scholar
• Livsey JE, Routledge J, Burns M, Swindell R, Davidson SE, Cowan RA, et al. Scoring of treatment-related late effects in prostate cancer. Radiother Oncol 2002;65:109–21.
   PubMed Web of Science ®Google Scholar
• Rubin P, Constine LS, Fajardo LF, Phillips TL, Wasserman TH. RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys 1995;31:1041–2.
   PubMed Web of Science ®Google Scholar
• Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67–74.
   PubMed Web of Science ®Google Scholar
• Bakken AM, Ogreid P, Iversen J, Langberg CW. [Normal tissue radiation toxicity in radiotherapy of localized prostatic cancer]. TidsskrNor Laegeforen 1999;119:2017–21.
   PubMedGoogle Scholar
• Denekamp J, Bartelink H, Rubin P. Correction for the use of the SOMA LENT tables. Int J Radiat Oncol Biol Phys 1996;35:417.
   PubMed Web of Science ®Google Scholar
• Pavy JJ, Denekamp J, Letschert J, Littbrand B, Mornex F, Bernier J, et al. EORTC Late Effects Working Group. Late effects toxicity scoring: The SOMA scale. Radiother Oncol 1995;35:11–5.
   PubMed Web of Science ®Google Scholar
• Anacak Y, Yalman D, Ozsaran Z, Haydaroglu A. Late radiation effects to the rectum and bladder in gynecologic cancer patients: The comparison of LENT/SOMA and RTOG/EORTC late-effects scoring systems. Int J Radiat Oncol Biol Phys 2001;50:1107–12.
   PubMed Web of Science ®Google Scholar
• Lundby L, Laurberg S, Overgaard J. Is the LENT-SOMA scoring system useful to record late rectal toxicity?RadiotherOncol 2000;57(Suppl 1):S16.
   Google Scholar
• Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: Comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 2003;55:93–8.
   PubMed Web of Science ®Google Scholar
• Davidson SE, Trotti A, Ataman OU, Seong J, Lau FN, da Motta NW, et al. Improving the capture of adverse event data in clinical trials: The role of the International Atomic Energy Agency. Int J Radiat Oncol Biol Phys 2007;69:1218–21.
   PubMed Web of Science ®Google Scholar
• Fransson P, Lund JA, Damber JE, Klepp O, Wiklund F, Fossa S, et al. Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. Lancet Oncol 2009;10:370–80.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality- of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–76.
   PubMed Web of Science ®Google Scholar
• Widmark A, Fransson P, Tavelin B. Self-assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population. Cancer 1994;74:2520–32.
   PubMed Web of Science ®Google Scholar
• Feldman M, Friedman Lawrence S, Sleisinger Marvin H. Sleisinger & Fordtran’s gastrintestinal an liver disease; pathophysiology, diagnosis, management. Philadelphia: Saunders; 2003. p. 2048.
   Google Scholar
• Lilleby W, Fossa SD, Waehre HR, Olsen DR. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys 1999;43:735–43.
   PubMed Web of Science ®Google Scholar
• Jackson A, Marks LB, Bentzen SM, Eisbruch A, Yorke ED, Ten Haken RK, et al. The lessons of QUANTEC: Recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S155–60.
   Google Scholar
• Ganz PA, Gotay CC. Use of patient-reported outcomes in phase III cancer treatment trials: Lessons learned and future directions. J Clin Oncol 2007;25:5063–9.
   PubMed Web of Science ®Google Scholar
• Cleeland CS, Nakamura Y, Mendoza TR, Edwards KR, Douglas J, Serlin RC. Dimensions of the impact of cancer pain in a four country sample: New information from multidimensional scaling. Pain 1996;67:267–73.
   PubMed Web of Science ®Google Scholar
• Koller M, Aaronson NK, Blazeby J, Bottomley A, Dewolf L, Fayers P, et al. Translation procedures for standardised quality of life questionnaires: The European Organisation for Research and Treatment of Cancer (EORTC) approach. Eur J Cancer 2007;43:1810–20.
   PubMed Web of Science ®Google Scholar
• Basch E, Bennett A, Pietanza MC. Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events. J Natl Cancer Inst 2011;103:1808–10.
   PubMedGoogle Scholar
• Farnell DJ, Mandall P, Anandadas C, Routledge J, Burns MP, Logue JP, et al. Development of a patient- reported questionnaire for collecting toxicity data following prostate brachytherapy. Radiother Oncol 2010;97:136–42.
   PubMed Web of Science ®Google Scholar